OseltamivirResistant Pandemic (H1N1) 2009 in Patient with Impaired Immune System
To the Editor: We detail the development of oseltamivir-resistant pandemic (H1N1) 2009 in a chronically immunocompromised patient and the pitfalls encountered when treating such patients with neuraminidase inhibitors. On August 6, 2009, a 56-year-old man was seen in the emergency room of a local hospital with a 24-hour history of fever, myalgia, coryzal symptoms, and cough. He was on day 3 of a postexposure course of oseltamivir (75 mg 1×/d); infl uenza A had been presumptively diagnosed for his wife after she had similar symptoms. . By August 9, the patient was still febrile, and zanamivir (10 mg 2×/d) was started. Oseltamivir was given for a total of 7 d and zanamivir for 3 d.
Nose and throat swabs taken on August 21 still contained pandemic (H1N1) 2009 viral RNA. Real-time PCR and pyrosequencing demonstrated a histidine-to-tyrosine substitution (H275Y) in the neuraminidase gene associated with oseltamivir resistance (Respiratory Virus Unit, Centre for Infections, Health Protection Agency; methods not in public domain). A mixture of wild-type and resistant virus was present (A. Lackenby, pers. comm.). The sample from August 7 did not contain this mutation, suggesting a de novo H275Y substitution secondary to oseltamivir use.
The patient improved and was discharged on August 23 but returned for treatment on September 7 with worsening fever and cough. Nose and throat swabs obtained on September 11 were PCR negative, but follow-up samples on September 25 and October 1 contained detectable pandemic (H1N1) 2009 viral RNA. Because virus isolation was not performed, true infectivity remains unresolved, but intermittent detection suggests ongoing replication, such as that seen in other immunocompromised patients (2, 3) .
By February 3, 2010, a total of 225 cases of oseltamivir-resistant pandemic (H1N1) 2009 had been identifi ed worldwide; a high proportion of cases were in immunocompromised persons (4) . A minority of these mutations were detected in treatment-naive patients. Immunocompromised, particularly lymphopenic, patients shed virus for prolonged periods leading to longer treatment courses and viral shedding reviving on termination of treatment. Viral shedding for up to 18 months has been reported for seasonal infl uenza, which has important implications for infection control (5) . Our patient demonstrated that a single PCR-negative test does not reliably determine the end of viral shedding, which continued despite co-treatment with 2 neuraminidase inhibitors. Neuraminidase inhibitors interfere with the release of progeny infl uenza virus from their infected host cells. Effective treatment depends partially on immune system destruction of the foci of infection (6), or potential persistent viral particles can be released as soon as oseltamivir therapy is stopped. The low genetic barrier to oseltamivir means that resistance is a likely consequence of monotherapy in immunocompromised patients.
Concern about oseltamivir resistance has led to issuance of additional guidelines, especially in light of the transmission of resistant virus between immunocompromised patients on hospital wards in the United States and Wales (7, 8) . This fi nding suggests that immunocompromised patients should be treated with oseltamivir and zanamivir, or with zanamivir alone, for a minimum of 10 d. Patients should be retested for ongoing viral secretion every 5 d and negative results confi rmed with a follow-up sample after 48 h. Classic virus isolation in addition to molecular methods may also identify potentially infectious patients.
Prophylactic neuraminidase inhibitor use in such patients also needs to be addressed. Resistance is more likely with the reduced prophylactic dose of oseltamivir and is more likely to be a problem in immunocompromised patients. Zanamivir is now the drug of choice for prophylaxis for such patients, although some experts propose no prophylaxis and instead early treatment after symptom onset (9) .
Immunocompromised patients are more likely to shed virus for prolonged periods and are more likely to develop oseltamivir-resistance, especially when this drug is used as monotherapy. Further clinical experience and trials will support or refute newer guidelines on the management of pandemic (H1N1) 2009 in such patients. To the Editor: Contrary to norovirus (NoV) infections, sapovirus (SaV) is believed to affect mainly young children (1) , although recent studies show that SaV is present in all age groups (2, 3) . SaV has been classifi ed into 5 genogroups, of which GI, GII, GIV, and GV affect humans (4) . SaV can be transmitted in various ways, including person-to-person fecal-oral route, by aerosol, and by consumption of contaminated food or water (5) . Outbreaks of SaV have been reported in various settings but are less common than NoV outbreaks (1, 6) .
During October 2-7, 2008, an outbreak of gastroenteritis occurred in a rehabilitation center in Upper Austria. Signs including diarrhea, vomiting, and fever developed in 21 adult patients and 12 staff members. The observed signs and the likely incubation period initially suggested NoV as the cause of the outbreak. Stool specimens of 10 patients were collected and submitted to the Institute for Medical Microbiology and Hygiene in Graz.
Along with microbiologic investigations, infection control measures were introduced by local authorities on each affected ward. The earliest reported onset of illness was on October 2, 2008, in a 52-year-old woman on the third fl oor. The next day 2 additional patients on the same fl oor and 1 member of the kitchen staff showed symptoms. Another 7 patients, on 3 different fl oors, and 2 of the medical staff suffered from symptoms the following day (October 4). The outbreak peaked with 11 cases 3 days after the initial episode of vomiting. An additional 9 persons became infected (5 patients, a doctor, janitor, psychotherapist, and kitchen worker) within the following 2 days. The affected patients were pre-
